Core Insights - IBA has secured a contract to supply a ProteusONE compact proton therapy solution to MacKay Memorial Hospital in New Taipei City, Taiwan, marking the fourth order of this system in Taiwan and reinforcing IBA's market leadership in proton therapy solutions [1][2][3] Company Overview - IBA (Ion Beam Applications S.A.) is recognized as the world leader in particle accelerator technology and the leading provider of proton therapy solutions for cancer treatment [5] - The company employs approximately 2,100 people globally and is a certified B Corporation, meeting high standards of social and environmental performance [5] Product Details - The contract includes the delivery and installation of the ProteusONE system along with a comprehensive Quality Assurance package from IBA Dosimetry [2] - ProteusONE is designed to incorporate the latest technological advancements, ensuring users benefit from state-of-the-art innovation, and will feature DynamicARC beam delivery capabilities pending regulatory clearance [2] Market Position - The typical end-user price for a ProteusONE system with a multi-year maintenance contract ranges between EUR 35 and 45 million [3] - IBA's success in securing contracts in Asia highlights the strength of its innovation strategy and commitment to partnerships, further consolidating its position in the global proton therapy market [3] Hospital Partnership - MacKay Memorial Hospital aims to start treating patients with the new system in 2029, enhancing its ability to provide advanced cancer treatment [2][3] - The collaboration with IBA represents a significant milestone in MacKay Memorial Hospital's commitment to delivering world-class care and expanding access to innovative therapies [3]